XTL Biopharmaceuticals Ltd. XTLB
2.20
(0.21)
(8.71%)
as of 25 Sep
- Market cap
- $9.7M
- P/E
- 0.0×
Follow XTLB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — | — | — | — | — | — | — |
P/S ratio |
— | 5.63 | — | — | — | — | — | — | — | — |
P/FCF ratio |
— | 0.00 | — | — | — | — | — | — | — | — |
P/Operating CF |
— | (17.84) | — | — | — | — | — | — | — | — |
P/B ratio |
— | 1.93 | — | — | — | — | — | — | — | — |
Price to Tangible BV |
— | 0.00 | — | — | — | — | — | — | — | — |
EV/Sales |
— | 4.84 | — | — | — | — | — | — | — | — |
EV/EBITDA |
— | 0.00 | — | — | — | — | — | — | — | — |
EV/Operating CF |
— | (2.70) | — | — | — | — | — | — | — | — |
EV/FCF |
— | (2.56) | — | — | — | — | — | — | — | — |
Quick Ratio |
0.18 | 0.56 | 9.93 | 19.90 | 26.52 | 23.79 | 29.44 | 32.39 | 12.33 | 8.35 |
Current Ratio |
0.40 | 0.61 | 9.93 | 20.35 | 27.00 | 24.10 | 29.44 | 32.39 | 20.69 | 8.35 |
Net Debt/EBITDA |
(0.11) | 1.74 | 2.62 | 4.23 | 5.95 | 6.38 | 7.99 | 10.24 | 2.88 | 1.42 |
Debt/Assets |
162.05% | 1.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(1.06) | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.15 | 1.58 | 0.40 | 0.67 | (2.41) | 0.29 | 0.67 | (0.27) | 1.44 | 0.68 |
Capex/Depreciation |
— | (0.27) | — | 0.00 | 0.00 | (1.00) | 0.00 | — | 0.96 | (0.08) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (269.02%) | (26.83%) | (57.31%) | (28.89%) | 9.73% | (55.78%) | (17.61%) | 50.01% | (24.77%) | (67.20%) | |
| (159.91%) | (18.71%) | (53.90%) | (24.95%) | 6.63% | (43.08%) | (17.06%) | 39.39% | (16.27%) | (61.03%) | |
ROIC |
0.00% | (10.93%) | (223.42%) | (197.84%) | 0.00% | 0.00% | (208.83%) | (247.81%) | (2,433.59%) | (630.17%) |
Return on Tangible Assets |
2,743.70% | 151.03% | (96.85%) | (37.25%) | 7.24% | (50.33%) | (20.41%) | 37.60% | (13.22%) | (104.56%) |
Average Days of Receivables |
— | 0.00 | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.82 | 0.16 | 0.09 | 0.06 | 0.06 | 0.05 | 0.04 | 0.06 | 0.08 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | (0.14) | — | — | — | — | — | — | — | — |
Graham Number |
— | 0.00 | — | — | — | — | — | — | — | — |
Earnings Yield |
— | (3.45%) | — | — | — | — | — | — | — | — |
Free Cash Flow Yield |
— | (33.61%) | — | — | — | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.11) | (0.24) | (0.52) | (0.66) | (0.79) | (0.66) | (0.71) | (0.63) | (0.96) | (2.53) |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.10) |
Free Cash Flow per Share |
(0.11) | (0.25) | (0.52) | (0.66) | (0.79) | (0.66) | (0.71) | (0.63) | (0.96) | (2.62) |
Cash per Share |
0.01 | 0.17 | 1.47 | 2.73 | 4.61 | 4.70 | 5.23 | 6.32 | 3.05 | 3.55 |
Shareholders Equity per Share |
(0.03) | 0.81 | 1.63 | 2.94 | 4.01 | 2.81 | 5.43 | 6.47 | 3.08 | 3.92 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.03) | 0.81 | 1.63 | 2.94 | 4.01 | 2.81 | 5.43 | 6.47 | 3.08 | 3.92 |
Free Cash Flow |
(1.02) | (1.67) | (0.71) | (0.90) | (1.05) | (0.85) | (0.91) | (0.82) | (1.12) | (1.80) |
Working Capital |
(0.25) | (0.87) | 1.84 | 3.62 | 6.01 | 5.87 | 6.60 | 7.94 | 5.91 | 2.42 |
Capital Expenditures |
— | (0.05) | — | — | — | 0.00 | 0.00 | — | 0.00 | (0.07) |
Net Current Asset Value |
(0.25) | (1.77) | 1.84 | 3.62 | 4.95 | 3.23 | 6.60 | 7.94 | 3.24 | 2.42 |
EV/EBIT |
— | 0.00 | — | — | — | — | — | — | — | — |
Capex to Sales |
— | 0.00 | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
— | 0.00 | — | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | 1.06 | — | 0.00 | 1.00 | 0.50 | 0.00 | — | 0.00 | 85.10 |
Cash ROIC |
(1,126.37%) | (26.88%) | (16.73%) | (11.67%) | (9.16%) | (8.83%) | (6.64%) | (4.96%) | (15.61%) | (34.02%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
Average Receivables |
— | 0.07 | 0.07 | — | — | — | 0.09 | 0.09 | 0.22 | 0.26 |
Average Payables |
0.47 | 0.50 | 0.20 | 0.21 | 0.24 | 0.24 | 0.24 | 0.28 | 0.16 | 0.07 |
Average Assets |
4.36 | 5.49 | 3.31 | 5.40 | 6.56 | 6.86 | 7.89 | 7.58 | 4.80 | 4.17 |
Average Common Equity |
2.59 | 3.83 | 3.11 | 4.67 | 4.47 | 5.30 | 7.65 | 5.97 | 3.15 | 3.79 |
Columns are period end dates